Windtree Therapeutics
Windtree Therapeutics is an American biotechnology company focused on developing drug products for respiratory disease, particularly pulmonary surfactant therapies and aerosol-delivery technologies.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Windtree Therapeutics, Inc. is an American biotechnology and pharmaceutical development company headquartered in Warrington, Pennsylvania. The business was established in 1992 under the name Discovery Laboratories and later adopted the Windtree Therapeutics name in 2016. Its development work has centered on pulmonary medicine, with particular emphasis on therapies and delivery systems intended for patients with respiratory disease. The company's principal technology platform has been the synthetic KL4 pulmonary surfactant program. Pulmonary surfactant is a naturally occurring substance in the lungs that helps maintain normal respiratory function by reducing surface tension in the alveoli. Windtree's synthetic surfactant products were designed to reproduce important functional characteristics of natural pulmonary surfactant and to be administered to patients whose lungs do not produce or maintain adequate surfactant activity. Surfaxin, also known as lucinactant intratracheal suspension, was one of the company's principal products. It is a synthetic, peptide-containing surfactant based on the KL4 technology. The company developed a capillary aerosol-generating approach intended to deliver surfactant to the lungs. Windtree also advanced Aerosurf, a drug-device combination designed to administer aerosolized KL4 surfactant to premature infants at risk of respiratory distress syndrome. This program was aimed at addressing the clinical and practical challenges associated with treating premature infants who may require respiratory support while avoiding or reducing the invasiveness of conventional surfactant administration. Another part of the company's product portfolio has been Afectair, a range of disposable aerosol-conducting airway connectors. These devices were developed to support the delivery of aerosolized medicines through respiratory equipment and form part of Windtree's broader interest in combining pharmaceutical formulations with specialized delivery systems. The company's research program included clinical and preclinical work in neonatal respiratory distress syndrome and other forms of lung injury. In 2013, the U.S. Food and Drug Administration cleared an investigational new drug application for a phase II clinical program involving aerosolized KL4 surfactant. The program was structured to examine safety and tolerability and to help identify an appropriate dose for premature infants with respiratory distress syndrome. The company also pursued research into acute lung injury, including projects supported by government-sponsored biodefense initiatives associated with the Project BioShield Act and the Pandemic and All-Hazards Preparedness Act. Windtree has also used partnerships to advance its commercial and development activities. The company entered an alliance with Laboratorios del Dr. Esteve, S.A., a Spanish pharmaceutical company. The available reference material does not provide sufficient detail to establish the full scope, duration, or current status of that relationship. The 2016 renaming from Discovery Laboratories to Windtree Therapeutics marked a corporate identity change while preserving the company's focus on pulmonary drug development and drug-delivery technologies. Publicly described activities have included regulatory interactions, clinical development, technology development, and partnership activity. The available material does not establish the company's complete current pipeline, financial position, ownership structure, executive roster, or present commercial status for each product. Accordingly, this dossier treats Windtree Therapeutics as an active biotechnology company but flags the entry for review where current corporate details are unavailable.
History
Windtree Therapeutics traces its origins to 1992, when it was established as Discovery Laboratories in the United States. From its early development, the company concentrated on respiratory medicine rather than operating as a broad diversified pharmaceutical group. Its principal scientific interest was pulmonary surfactant technology, especially synthetic formulations intended to replicate key functions of the natural surfactant found in the lungs. The company's best-known development programs were associated with KL4, a synthetic peptide-containing surfactant technology. Surfaxin, also identified as lucinactant intratracheal suspension, was developed as a pulmonary surfactant product for preventing respiratory distress syndrome in premature infants. The company paired the formulation with delivery research, including a capillary aerosol-generating technology intended to transport the medicine into the lung. Aerosurf represented a further development of this approach. It was described as a drug-device combination intended to deliver aerosolized KL4 surfactant to premature infants with respiratory distress syndrome. The program addressed a significant technical and clinical problem: surfactant therapy for premature infants traditionally involves delivery methods that can be invasive, while aerosolized administration requires specialized formulation and device engineering. Windtree's work therefore combined pharmaceutical research with respiratory-device development. The company also developed Afectair disposable aerosol-conducting airway connectors. These devices supported aerosol delivery through respiratory airways and reflected the company's strategy of developing complementary equipment alongside drug products. The portfolio consequently included both therapeutic formulations and delivery components. In 2012, Discovery Laboratories began four research projects investigating the use of KL4 surfactant technology for acute lung injury. The projects were connected with government-sponsored biodefense initiatives under the Project BioShield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006. This expanded the potential application of the platform beyond neonatal respiratory distress syndrome and into broader forms of serious pulmonary injury. Regulatory and clinical development activity continued in 2013. In October, the company received FDA agreement concerning an update to Surfaxin information related to the prevention of respiratory distress syndrome in premature infants. In November, the FDA had cleared the investigational new drug application supporting a phase II program for aerosolized KL4. The two-step study plan was intended to assess safety and tolerability and to identify an appropriate dose for premature infants with respiratory distress syndrome. Windtree also entered into an alliance with Laboratorios del Dr. Esteve, S.A. The available source identifies the relationship but does not provide enough information to describe its commercial terms, geographic scope, or later outcome. Such alliances were relevant to a company whose products required both clinical development and specialized commercialization capabilities. In 2016, Discovery Laboratories changed its name to Windtree Therapeutics, Inc. The renaming created the Windtree identity used for the company's later operations while retaining its established emphasis on pulmonary medicines and drug-delivery technologies. The available reference material does not supply a complete account of subsequent clinical outcomes, product approvals, management changes, ownership, financial performance, or the current status of every historical product program. Those areas require additional verification before they can be added to the encyclopedia record.
- 2016
Company renamed Windtree Therapeutics
[1]Discovery Laboratories changed its corporate name to Windtree Therapeutics, Inc.
- 2013
FDA-related Surfaxin update
[1]The company received FDA agreement concerning an update to Surfaxin information for preventing respiratory distress syndrome in premature infants.
- 2013
Phase II aerosolized KL4 program begins
[1]Following FDA clearance of an investigational new drug application, the company began a phase II program evaluating aerosolized KL4 surfactant in premature infants with respiratory distress syndrome.
- 2012
KL4 technology research expands to acute lung injury
[1]Four research projects were initiated to examine KL4 surfactant technology for acute lung injury, with support described as coming from government-sponsored biodefense initiatives.
- 1992
Company established as Discovery Laboratories
[1]The company was established in the United States under the name Discovery Laboratories and focused on respiratory drug development.
Products and positioning
A respiratory-focused biotechnology company developing synthetic pulmonary surfactants, aerosolized drug-device combinations, and supporting airway-delivery technologies.
Synthetic pulmonary surfactant
Surfaxin
Surfaxin, also known as lucinactant intratracheal suspension, is a synthetic peptide-containing pulmonary surfactant based on the KL4 technology. It was developed to resemble important functional properties of natural pulmonary surfactant and was associated with prevention of respiratory distress syndrome in premature infants. The formulation was studied alongside specialized delivery technologies intended to administer surfactant to the lungs.
Drug-device combination
Aerosurf
Aerosurf is a drug-device combination designed to deliver aerosolized KL4 pulmonary surfactant to premature infants at risk of respiratory distress syndrome. Its development combined a synthetic surfactant formulation with an aerosol-delivery approach, aiming to address the challenges of administering surfactant therapy through less invasive respiratory treatment methods.
Respiratory delivery device
Afectair
Afectair devices are disposable aerosol-conducting airway connectors intended to support the delivery of aerosolized medicines through respiratory equipment. They represent the device component of Windtree's broader respiratory platform and complement the company's work on inhaled and aerosolized pulmonary therapies.
Brand decisions
2016
Corporate rebranding from Discovery Laboratories to Windtree TherapeuticsStrategyBackground
The company had operated under the Discovery Laboratories name while developing pulmonary surfactants and aerosol-delivery technologies.
Action taken
Discovery Laboratories changed its corporate name to Windtree Therapeutics, Inc.
Aftermath
The Windtree Therapeutics identity became the name associated with the company's respiratory drug-development activities. The available material does not establish the broader commercial or strategic effects of the renaming.
Recent events
- 2016
Discovery Laboratories changes name to Windtree Therapeutics[1]
Other
Discovery Laboratories adopted the Windtree Therapeutics name, establishing the corporate identity used in the reference material for the company’s pulmonary drug-development activities.
- 2013
Discovery Laboratories begins phase II aerosolized KL4 clinical program[1]
Other
Discovery Laboratories began a phase II clinical program for aerosolized KL4 surfactant after the U.S. Food and Drug Administration cleared the investigational new drug application. The program was designed to evaluate safety and tolerability and to help determine an appropriate dose for premature infants with respiratory distress syndrome.
- 2013
FDA agrees to updated Surfaxin information[1]
Regulation
The company received FDA agreement concerning an update to information for Surfaxin, or lucinactant intratracheal suspension, in connection with its use to prevent respiratory distress syndrome in premature infants.
- 2012
KL4 research expands into acute lung injury[1]
Other
Discovery Laboratories initiated four research projects examining its KL4 surfactant technology for acute lung injury. The projects were described as receiving support from government-sponsored biodefense initiatives.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/windtree-therapeutics · Editorial policy · How profiles are compiled